16:57 EST Aardvark Therapeutics (AARD) up 9% at $10.10 after Raymond James Strong Buy initiation
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics initiated with a Strong Buy at Raymond James
- Aardvark Therapeutics Reports Q3 2025 Financial Results
- Aardvark Therapeutics reports Q3 EPS (75c), consensus (80c)
- Aardvark Thera sees cash, equivalents sufficient to fund operations into 2027
- Aardvark Therapeutics, Inc.: Undervalued Potential in the Obesity Treatment Market with Promising Pipeline